Skip to main content

Site notifications

(Approval lapsed) GASTROGRAFIN amidotrizoate meglumine sodium amidotrizoate oral solution (Bayer, UK)

Section 19A approved medicine
(Approval lapsed) GASTROGRAFIN amidotrizoate meglumine sodium amidotrizoate oral solution (Bayer, UK)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Expired
Medicines in short supply/unavailable
GASTROGRAFIN oral liquid bottle - ARTG 10684
Indication(s)

Gastrografin is a contrast medium for the examination of the gastrointestinal tract. It can be administered orally and as an enema and is primarily indicated in cases in which the use of barium sulfate is unsatisfactory, undesirable or contraindicated. Among these are: - suspected partial or complete stenosis -acute haemorrhage -threatening perforation (peptic ulcer, diverticulum) -other acute conditions which are likely to require surgery -after resection of the stomach or the intestine (danger of perforation or leak) - megacolon -visualisation of a foreign body or tumour before endoscopy -visualisation of gastrointestinal fistula In addition to these conditions Gastrografin can generally be used for the same purposes as barium sulfate with the exception of the visualisation of mucosal diseases. Due to the insufficient coating properties of Gastrografin, barium sulfate should be used for single or double contrast techniques. -Early diagnosis of a radiologically undetectable perforation or anastomotic defect in the oesophagus or gastrointestinal tract. -Treatment of meconium ileus. -Computerised tomography in the abdominal region. The danger of false diagnoses is significantly reduced if the intestine is opacified with Gastrografin, especially for differential diagnoses in the minor pelvis. Gastrografin facilitates delimitation of the intestine from neighbouring organs and permits an assessment of changes in the shape of the pancreas.

Images
Picture of GASTROGRAFIN amidotrizoate meglumine sodium amidotrizoate oral solution (Bayer, UK)

Help us improve the Therapeutic Goods Administration site